{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:52:08Z","timestamp":1786935128515,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ecl.2025.03.018","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T07:14:40Z","timestamp":1745219680000},"page":"521-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Familial Thyroid Cancers Syndromes"],"prefix":"10.1016","volume":"54","author":[{"given":"Reza","family":"Pishdad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Barbesino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ecl.2025.03.018_bib1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.cellsig.2014.03.032","article-title":"Mechanisms of RET signaling in cancer: current and future implications for targeted therapy","volume":"26","author":"Plaza-Menacho","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.ecl.2025.03.018_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.semcancer.2021.03.035","article-title":"Multiple endocrine neoplasia type 2: a review","volume":"79","author":"Mathiesen","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.018_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/imj.14394","article-title":"Multiple endocrine neoplasia: an update","volume":"49","author":"McDonnell","year":"2019","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1210\/jc.2017-01884","article-title":"Long-term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium","volume":"103","author":"Raue","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib5","article-title":"A benign medullary thyroid cancer","volume":"14","author":"Pishdad","year":"2022","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.018_bib7","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1210\/jc.2017-02529","article-title":"Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer","volume":"103","author":"Loveday","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/humu.23430","article-title":"Genotype-specific progression of hereditary medullary thyroid cancer","volume":"39","author":"Machens","year":"2018","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12020-021-02895-8","article-title":"Controversy on the management of patients carrying RET p.V804M mutation","volume":"75","author":"Alzahrani","year":"2022","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.018_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archsurg.142.3.289","article-title":"Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis","volume":"142","author":"Machens","year":"2007","journal-title":"Arch Surg"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.018_bib11","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.018_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.018_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ecl.2025.03.018_bib14","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.018_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.018_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0889-8529(18)30121-X","article-title":"Multiple endocrine neoplasia type 2. Clinical features and screening","volume":"23","author":"Raue","year":"1994","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.018_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2796.1995.tb01211.x","article-title":"Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group","volume":"238","author":"Modigliani","year":"1995","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00000478-198004000-00003","article-title":"Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrime neoplasia, type 2","volume":"4","author":"Webb","year":"1980","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0889-8529(18)30123-3","article-title":"Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management","volume":"23","author":"Evans","year":"1994","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.018_bib21","doi-asserted-by":"crossref","first-page":"T135","DOI":"10.1530\/ERC-15-0175","article-title":"15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma","volume":"22","author":"Castinetti","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.ecl.2025.03.018_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.33","article-title":"Primary hyperparathyroidism","volume":"2","author":"Bilezikian","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.018_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2010.02.001","article-title":"Multiple endocrine neoplasia type 2","volume":"24","author":"Wohllk","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.018_bib25","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib26","doi-asserted-by":"crossref","first-page":"T41","DOI":"10.1530\/ERC-17-0202","article-title":"Advances in risk-oriented surgery for multiple endocrine neoplasia type 2","volume":"25","author":"Machens","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.03.018_bib27","first-page":"S66","article-title":"Hirschsprung\u2019s disease. Management","volume":"60","author":"Morera","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1365-2265.2003.01782.x","article-title":"Frequent association between MEN 2A and cutaneous lichen amyloidosis","volume":"59","author":"Verga","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1210\/jcem-43-2-428","article-title":"Preoperative diagnosis of occult parathyroid hyperplasia by calcium infusion in patients with multiple endocrine neoplasia, type 2a","volume":"43","author":"Heath","year":"1976","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.03.018_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-052218-125823","article-title":"The clinical spectrum of PTEN mutations","volume":"71","author":"Yehia","year":"2020","journal-title":"Annu Rev Med"},{"issue":"9","key":"10.1016\/j.ecl.2025.03.018_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/gim.2012.51","article-title":"Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome","volume":"14","author":"Mester","year":"2012","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib33","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41467-020-15943-0","article-title":"Multi-model functionalization of disease-associated PTEN missense mutations identifies multiple molecular mechanisms underlying protein dysfunction","volume":"11","author":"Post","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.018_bib34","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN guidelines(R) insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.surg.2012.08.055","article-title":"Should patients with Cowden syndrome undergo prophylactic thyroidectomy?","volume":"152","author":"Milas","year":"2012","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/cge.13875","article-title":"A review on age-related cancer risks in PTEN hamartoma tumor syndrome","volume":"99","author":"Hendricks","year":"2021","journal-title":"Clin Genet"},{"key":"10.1016\/j.ecl.2025.03.018_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-4-22","article-title":"Familial adenomatous polyposis","volume":"4","author":"Half","year":"2009","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.018_bib38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/thy.2014.0107","article-title":"Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance","volume":"25","author":"Feng","year":"2015","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.018_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.cgh.2006.10.019","article-title":"Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations","volume":"5","author":"Herraiz","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.018_bib40","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/ERC-17-0014","article-title":"Cribriform-morular variant of papillary thyroid carcinoma: a distinctive type of thyroid cancer","volume":"24","author":"Lam","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.018_bib41","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1158\/1078-0432.CCR-17-3089","article-title":"DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies","volume":"24","author":"Schultz","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.path.2022.09.010","article-title":"On the chopping block: overview of DICER1 mutations in endocrine and neuroendocrine neoplasms","volume":"16","author":"Juhlin","year":"2023","journal-title":"Surg Pathol Clin"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.018_bib43","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1210\/jc.2016-2954","article-title":"Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study","volume":"102","author":"Khan","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2025.03.018_bib44","doi-asserted-by":"crossref","first-page":"e2214","DOI":"10.1210\/clinem\/dgae107","article-title":"Clinically relevant germline variants in children with nonmedullary thyroid cancer","volume":"109","author":"van der Tuin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib45","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1515\/jpem-2021-0741","article-title":"Genomic landscape of sporadic pediatric differentiated thyroid cancers: a systematic review and meta-analysis","volume":"35","author":"Satapathy","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib46","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00428-021-03212-4","article-title":"Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform","volume":"480","author":"Ghossein","year":"2022","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.018_bib47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.29426","article-title":"CHEK2 mutations and the risk of papillary thyroid cancer","volume":"137","author":"Siolek","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.018_bib48","first-page":"477","article-title":"CHEK2 founder variants and thyroid cancer risk","volume":"34","author":"Brock","year":"2024","journal-title":"Thyroid"},{"issue":"21","key":"10.1016\/j.ecl.2025.03.018_bib49","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.018_bib50","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jamaoncol.2016.6389","article-title":"Frequency of thyroid carcinoma in Brazilian TP53 p.R337H carriers with Li fraumeni syndrome","volume":"3","author":"Formiga","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2025.03.018_bib51","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1210\/jcem.82.7.4079","article-title":"Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex)","volume":"82","author":"Stratakis","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"10.1016\/j.ecl.2025.03.018_bib52","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1056\/NEJMoa2300503","article-title":"Familial clonal hematopoiesis in a long telomere syndrome","volume":"388","author":"DeBoy","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib53","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ajhg.2024.04.006","article-title":"Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype","volume":"111","author":"DeBoy","year":"2024","journal-title":"Am J Hum Genet"},{"issue":"21","key":"10.1016\/j.ecl.2025.03.018_bib54","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jnci\/86.21.1600","article-title":"Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands","volume":"86","author":"Goldgar","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib55","first-page":"113","article-title":"Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway","volume":"10","author":"Frich","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.ecl.2025.03.018_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/thy.2006.16.181","article-title":"On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds","volume":"16","author":"Charkes","year":"2006","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.018_bib57","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1089\/thy.2016.0668","article-title":"Results of screening in familial non-medullary thyroid cancer","volume":"27","author":"Klubo-Gwiezdzinska","year":"2017","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ecl.2025.03.018_bib58","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12020-020-02250-3","article-title":"An update on familial nonmedullary thyroid cancer","volume":"68","author":"Ammar","year":"2020","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.018_bib59","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40618-020-01435-x","article-title":"Familial non-medullary thyroid cancer: a critical review","volume":"44","author":"Capezzone","year":"2021","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12022-020-09661-y","article-title":"Inherited follicular epithelial-derived thyroid carcinomas: from molecular biology to histological correlates","volume":"32","author":"Cameselle-Teijeiro","year":"2021","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12022-022-09705-5","article-title":"Overview of the 2022 WHO classification of familial endocrine tumor syndromes","volume":"33","author":"Nos\u00e9","year":"2022","journal-title":"Endocr Pathol"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib62","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/302164","article-title":"A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2","volume":"63","author":"Canzian","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.ecl.2025.03.018_bib63","first-page":"1758","article-title":"Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome","volume":"85","author":"Malchoff","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.03.018_bib64","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1210\/jc.2008-0449","article-title":"Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis","volume":"93","author":"Cavaco","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2025.03.018_bib65","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1210\/jcem.86.8.7725","article-title":"A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1","volume":"86","author":"Bevan","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.018_bib66","doi-asserted-by":"crossref","first-page":"E1674","DOI":"10.1210\/jc.2013-1941","article-title":"Genome-wide association study on differentiated thyroid cancer","volume":"98","author":"K\u00f6hler","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.03.018_bib67","doi-asserted-by":"crossref","first-page":"8922","DOI":"10.1038\/srep08922","article-title":"Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk","volume":"5","author":"Figlioli","year":"2015","journal-title":"Sci Rep"},{"issue":"31","key":"10.1016\/j.ecl.2025.03.018_bib68","article-title":"Germ-line mutations in","volume":"118","author":"Zhao","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ecl.2025.03.018_bib69","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.18632\/oncotarget.14129","article-title":"Variants in microRNA genes in familial papillary thyroid carcinoma","volume":"8","author":"Tomsic","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ecl.2025.03.018_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/biom9100605","article-title":"Whole genome sequencing of familial non-medullary thyroid cancer identifies germline alterations in MAPK\/ERK and PI3K\/AKT signaling pathways","volume":"9","author":"Srivastava","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ecl.2025.03.018_bib71","article-title":"Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer","volume":"14","author":"Jiang","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2025.03.018_bib72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/thy.2009.0406","article-title":"Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study","volume":"21","author":"Robenshtok","year":"2011","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ecl.2025.03.018_bib73","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/EJE-14-0960","article-title":"Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis","volume":"172","author":"Wang","year":"2015","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:03:50Z","timestamp":1753484630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0889852925000404"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.018","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial Thyroid Cancers Syndromes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}